Young Rok

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 726 citations · Full text

Medicine, Hematology, Oncology +12

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

Catherine Thiéblemont, Tycel Phillips, Hervé Ghesquières et al. · Journal of Clinical Oncology · 2022 · 523 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Experiences and Attitudes of Patients With Terminal Cancer and Their Family Caregivers Toward the Disclosure of Terminal Illness

Young Ho Yun, Yong Chol Kwon, Myung Kyung Lee et al. · Journal of Clinical Oncology · 2010 · 146 citations · Full text

Medicine, Oncology, End-of-life Care +16

Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial

Catherine Thiéblemont, Yasmin Karimi, Hervé Ghesquières et al. · Leukemia · 2024 · 119 citations · Full text

Medicine, Oncology, Hematologic Oncology +7

Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)

Yu Ri Kim, Jin Seok Kim, Yoo Hong Min et al. · Journal of Hematology & Oncology · 2012 · 97 citations · Full text

Medicine, Oncology, Chemotherapy +10